Effects of Vitamin D receptor activation and dietary sodium restriction on residual albuminuria in CKD: The ViRTUE-CKD trial

Journal of the American Society of Nephrology

Volumn 28, Issue 4, 2017, Pages 1296-1305

  Keyzer, Charlotte A ^a   Van Breda, G Fenna ^b   Vervloet, Marc G ^b   De Jong, Maarten A ^a   Laverman, Gozewijn D ^c   Hemmelder, Marc H ^d   Janssen, Wilbert M T ^e   Lambers Heerspink, Hiddo J ^a   Kwakernaak, Arjan J ^a   Bakker, Stephan J L ^a   Navis, Gerjan ^a   De Borst, Martin H ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c Zorggroep Twente   (Netherlands)

^d MEDICAL CENTER LEEUWARDEN   (Netherlands)

^e MARTINI HOSPITAL   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; CALCIUM; PARICALCITOL; PHOSPHATE; RAMIPRIL; RENIN; SODIUM; VITAMIN D RECEPTOR; CALCITRIOL RECEPTOR; ERGOCALCIFEROL;

ALBUMIN BLOOD LEVEL; ALBUMIN TO CREATININE RATIO; ALBUMINURIA; ARTICLE; BLOOD PRESSURE; CALCIUM BLOOD LEVEL; CALCIUM EXCRETION; CHRONIC KIDNEY FAILURE; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE CLEARANCE; CROSSOVER PROCEDURE; DIETARY COMPLIANCE; DRUG DOSE REDUCTION; DRUG EFFICACY; EXTRACELLULAR SPACE; HUMAN; HYPERCALCEMIA; MEAN ARTERIAL PRESSURE; MEDICATION COMPLIANCE; MULTICENTER STUDY; PHOSPHATE BLOOD LEVEL; PLASMA RENIN ACTIVITY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RENAL SYSTEM PARAMETERS; SODIUM BLOOD LEVEL; SODIUM RESTRICTION; URINARY EXCRETION; WEIGHT REDUCTION; CLINICAL TRIAL; COMPLICATION; DOUBLE BLIND PROCEDURE; MULTIMODALITY CANCER THERAPY; PHYSIOLOGY;

ALBUMINURIA; COMBINED MODALITY THERAPY; CROSS-OVER STUDIES; DIET, SODIUM-RESTRICTED; DOUBLE-BLIND METHOD; ERGOCALCIFEROLS; HUMANS; RECEPTORS, CALCITRIOL; RENAL INSUFFICIENCY, CHRONIC;

EID: 85021847614     PISSN: 10466673     EISSN: 15333450     Source Type: Journal    
DOI: 10.1681/ASN.2016040407     Document Type: Article

References (46)

1. Zucchelli P, Zuccalà A, Borghi M, Fusaroli M, Sasdelli M, Stallone C, Sanna G, Gaggi R: Long-term comparison between captopril and nifedipine in the progression of renal insufficiency. Kidney Int 42: 452-458, 1992
2. MaschioG, Alberti D, JaninG, Locatelli F, Mann JF, MotoleseM, Ponticelli C, Ritz E, Zucchelli P: Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The angiotensinconverting-enzyme inhibition in progressive renal insufficiency study group. NEngl J Med 334: 939-945, 1996
3. GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia): Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). Lancet 349: 1857-1863, 1997
4. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, DagenaisG: Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The heart outcomes prevention evaluation study investigators. N Engl J Med 342: 145-153, 2000
5. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S; RENAAL Study Investigators: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345: 861-869, 2001
6. Ruggenenti P, Perna A, Remuzzi G; GISEN Group Investigators: Retarding progression of chronic renal disease: The neglected issue of residual proteinuria. Kidney Int 63: 2254-2261, 2003
7. Holtkamp FA, de Zeeuw D, de Graeff PA, Laverman GD, Berl T, Remuzzi G, Packham D, Lewis JB, Parving HH, Lambers Heerspink HJ: Albuminuria and blood pressure, independent targets for cardioprotective therapy in patients with diabetes and nephropathy: A post hoc analysis of the combined RENAAL and IDNT trials. Eur Heart J 32: 1493-1499, 2011
8. Vogt L, Waanders F, Boomsma F, de Zeeuw D, Navis G: Effects of dietary sodiumand hydrochlorothiazide on the antiproteinuric efficacy of losartan. J Am Soc Nephrol 19: 999-1007, 2008
9. Slagman MC, Waanders F, Hemmelder MH, Woittiez AJ, JanssenWM, Lambers Heerspink HJ, Navis G, Laverman GD; HOlland NEphrology STudy Group: Moderate dietary sodium restriction added to angiotensin converting enzyme inhibition compared with dual blockade in lowering proteinuria and blood pressure: Randomised controlled trial. BMJ 343: D4366, 2011
10. Kwakernaak AJ, Krikken JA, Binnenmars SH, Visser FW, Hemmelder MH, Woittiez AJ, GroenH, LavermanGD, NavisG;Holland Nephrology Study (HONEST) Group: Effects of sodium restriction and hydrochlorothiazide on RAAS blockade efficacy in diabetic nephropathy: A randomised clinical trial. Lancet Diabetes Endocrinol 2: 385-395, 2014
11. Vegter S, Perna A, Postma MJ, Navis G, Remuzzi G, Ruggenenti P: Sodium intake, ACE inhibition, and progression to ESRD. J Am Soc Nephrol 23: 165-173, 2012
12. Lambers Heerspink HJ, Holtkamp FA, Parving HH, Navis GJ, Lewis JB, Ritz E, de Graeff PA, de Zeeuw D: Moderation of dietary sodium potentiates the renal and cardiovascular protective effects of angiotensin receptor blockers. Kidney Int 82: 330-337, 2012
13. Mizobuchi M, Morrissey J, Finch JL, Martin DR, Liapis H, Akizawa T, Slatopolsky E: Combination therapy with an angiotensin-converting enzymeinhibitor and a vitaminDanalog suppresses the progression of renal insufficiency in uremic rats. J Am Soc Nephrol 18: 1796-1806, 2007
14. Zhang Z, Zhang Y, Ning G, DebDK, Kong J, Li YC: Combination therapy with AT1 blocker and vitamin D analog markedly ameliorates diabetic nephropathy: Blockade of compensatory renin increase. Proc Natl Acad Sci U S A 105: 15896-15901, 2008
15. de Borst MH, Hajhosseiny R, Tamez H, Wenger J, Thadhani R, Goldsmith DJ: Active vitamin D treatment for reduction of residual proteinuria: A systematic review. J Am Soc Nephrol 24: 1863-1871, 2013
16. de Zeeuw D, Agarwal R, Amdahl M, Audhya P, Coyne D, Garimella T, Parving HH, Pritchett Y, Remuzzi G, Ritz E, Andress D: Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): A randomised controlled trial. Lancet 376: 1543-1551, 2010
17. Li YC, Kong J, Wei M, Chen ZF, Liu SQ, Cao LP: 1, 25-Dihydroxyvitamin D(3) is a negative endocrine regulator of the renin-angiotensin system. J Clin Invest 110: 229-238, 2002
18. Vaidya A, Sun B, Larson C, Forman JP, Williams JS: Vitamin D3 therapy corrects the tissue sensitivity to angiotensin ii akin to the action of a converting enzyme inhibitor in obese hypertensives: An interventional study. J Clin Endocrinol Metab 97: 2456-2465, 2012
19. Mirkovic K, Frenay AS, van den Born J, van Goor H, Navis G, de Borst MH;NIGRAMconsortium:Sodium restrictionpotentiates therenoprotective effects of combined vitamin D receptor activation and angiotensinconverting enzyme inhibition in established proteinuric nephropathy [published online ahead of print August 25, 2015]. Nephrol Dial Transplant doi:10.1093/ndt/gfv304
20. Keyzer CA, Lambers-Heerspink HJ, JoostenMM, Deetman PE, Gansevoort RT, Navis G, Kema IP, de Zeeuw D, Bakker SJ, de Borst MH; PREVEND Study Group: Plasma vitamin D level and change in albuminuria and eGFR according to sodium intake. Clin J Am Soc Nephrol 10: 2119-2127, 2015
21. De Nicola L, Conte G, Russo D, Gorini A, Minutolo R: Antiproteinuric effect of add-on paricalcitol in CKD patients under maximal tolerated inhibition of renin-angiotensin system: A prospective observational study. BMC Nephrol 13: 150, 2012
22. Agarwal R, Acharya M, Tian J, Hippensteel RL, Melnick JZ, Qiu P, Williams L, Batlle D: Antiproteinuric effect of oral paricalcitol in chronic kidney disease. Kidney Int 68: 2823-2828, 2005
23. Alborzi P, PatelNA, PetersonC, Bills JE, BekeleDM, Bunaye Z, Light RP, Agarwal R: Paricalcitol reduces albuminuria and inflammation in chronic kidney disease: A randomized double-blind pilot trial. Hypertension 52: 249-255, 2008
24. Fishbane S, Chittineni H, Packman M, Dutka P, Ali N, Durie N: Oral paricalcitol in the treatment of patients with CKD and proteinuria: A randomized trial. Am J Kidney Dis 54: 647-652, 2009
25. Larsen T, Mose FH, Bech JN, Pedersen EB: Effect of paricalcitol on renin and albuminuria in non-diabetic stage III-IV chronic kidney disease: A randomized placebo-controlled trial. BMC Nephrol 14: 163, 2013
26. Hojs N, Bevc S, Balon BP, Hojs R, Ekart R: Paricalcitol reduces proteinuria in non-dialysis chronic kidney disease patients. Ther ApherDial 17: 368-372, 2013
27. Heeg JE, de Jong PE, van der Hem GK, de Zeeuw D: Efficacy and variability of the antiproteinuric effect of ACE inhibition by lisinopril. Kidney Int 36: 272-279, 1989
28. Fabris B, Jackson B, Johnston CI: Salt blocks the renal benefits of ramipril in diabetic hypertensive rats. Hypertension 17: 497-503, 1991
29. Ying WZ, Sanders PW: Dietary salt modulates renal production of transforming growth factor-beta in rats. Am J Physiol 274: F635-F641, 1998
30. Kwakernaak AJ, Waanders F, Slagman MC, Dokter MM, Laverman GD, de Boer RA, Navis G: Sodiumrestriction on topof renin-angiotensin-aldosterone system blockade increases circulating levels of N-acetyl-seryl-aspartyl-lysylproline in chronic kidney disease patients. JHypertens 31: 2425-2432, 2013
31. Slagman MC, Nguyen TQ, Waanders F, Vogt L, Hemmelder MH, Laverman GD, Goldschmeding R, Navis G: Effects of antiproteinuric intervention on elevated connective tissue growth factor (CTGF/CCN-2) plasma and urine levels in nondiabetic nephropathy. Clin J Am Soc Nephrol 6: 1845-1850, 2011
32. de Borst MH, Navis G: Sodium intake, RAAS-blockade and progressive renal disease. Pharmacol Res 107: 344-351, 2016
33. Kuhlmann A, Haas CS, Gross ML, Reulbach U, Holzinger M, Schwarz U, Ritz E, Amann K: 1, 25-Dihydroxyvitamin D3 decreases podocyte loss and podocyte hypertrophy in the subtotally nephrectomized rat. Am J Physiol Renal Physiol 286: F526-F533, 2004
34. Zhang Y, Kong J, Deb DK, Chang A, Li YC: Vitamin D receptor attenuates renal fibrosis by suppressing the renin-angiotensin system. J Am Soc Nephrol 21: 966-973, 2010
35. YuanW, PanW, Kong J, ZhengW, Szeto FL, Wong KE, Cohen R, Klopot A, Zhang Z, Li YC: 1, 25-dihydroxyvitamin D3 suppresses renin gene transcription by blocking the activity of the cyclic AMP response element in the renin gene promoter. JBiol Chem282: 29821-29830, 2007
36. He W, Kang YS, Dai C, Liu Y: Blockade of Wnt/b-catenin signaling by paricalcitol ameliorates proteinuria and kidney injury. J Am Soc Nephrol 22: 90-103, 2011
37. SchwarzU, Amann K, Orth SR, SimonavicieneA, Wessels S, Ritz E: Effect of 1, 25 (OH)2 vitamin D3 on glomerulosclerosis in subtotally nephrectomized rats. Kidney Int 53: 1696-1705, 1998
38. de Boer IH, Sachs M, Hoofnagle AN, Utzschneider KM, Kahn SE, Kestenbaum B, Himmelfarb J: Paricalcitol does not improve glucose metabolism in patients with stage 3-4 chronic kidney disease. Kidney Int 83: 323-330, 2013
39. Lundwall K, Jörneskog G, Jacobson SH, Spaak J: Paricalcitol, microvascular and endothelial function in non-diabetic chronic kidney disease: A randomized trial. Am J Nephrol 42: 265-273, 2015
40. Beveridge LA, Struthers AD, Khan F, Jorde R, Scragg R, Macdonald HM, Alvarez JA, Boxer RS, Dalbeni A, Gepner AD, Isbel NM, Larsen T, Nagpal J, Petchey WG, Stricker H, Strobel F, Tangpricha V, Toxqui L, Vaquero MP, Wamberg L, Zittermann A, Witham MD; D-PRESSURE Collaboration: Effect of vitamin D supplementation on blood pressure: A systematic review and meta-analysis incorporating individual patient data. JAMA Intern Med 175: 745-754, 2015
41. Apperloo AJ, de Zeeuw D, de Jong PE: A short-term antihypertensive treatment-induced fall in glomerular filtration rate predicts long-term stability of renal function. Kidney Int 51: 793-797, 1997
42. Holtkamp FA, de Zeeuw D, Thomas MC, Cooper ME, de Graeff PA, Hillege HJ, Parving HH, Brenner BM, Shahinfar S, Lambers Heerspink HJ: An acute fall in estimated glomerular filtration rate during treatment with losartan predicts a slower decrease in long-term renal function. Kidney Int 80: 282-287, 2011
43. Agarwal R, Hynson JE, Hecht TJ, Light RP, Sinha AD: Short-term vitamin D receptor activation increases serum creatinine due to increased production with no effect on the glomerular filtration rate. Kidney Int 80: 1073-1079, 2011
44. Scialla JJ, WolfM: Roles of phosphate and fibroblast growth factor 23 in cardiovascular disease. Nat Rev Nephrol 10: 268-278, 2014
45. KeyzerCA, de Jong MA, Fenna van BredaG, VervloetMG, LavermanGD, Hemmelder M, Janssen WM, Lambers Heerspink HJ, Navis G, de Borst MH; Holland Nephrology Study (HONEST) Network: Vitamin D receptor activator and dietary sodiumrestriction to reduce residual urinary albumin excretion in chronic kidney disease (ViRTUE study): Rationale and study protocol. Nephrol Dial Transplant 31: 1081-1087, 2016
46. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF III , Feldman HI, Kusek JW, Eggers P, Van Lente F, Greene T, Coresh J; CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration): A new equation to estimate glomerular filtration rate. Ann Intern Med 150: 604-612, 2009